Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

76.20USD
1:31pm EST
Change (% chg)

$1.06 (+1.41%)
Prev Close
$75.14
Open
$75.50
Day's High
$76.44
Day's Low
$75.40
Volume
518,476
Avg. Vol
1,991,650
52-wk High
$76.44
52-wk Low
$56.81

Select another date:

Tue, Feb 19 2019

U.S. joins case against Abbott's Alere over diabetic tests

The U.S. Justice Department on Tuesday said it has joined a whistleblower lawsuit alleging Abbott Laboratories' Alere Inc unit defrauded Medicare into paying for unnecessary testing supplies for diabetic patients.

Abbott's Alere to resolve securities fraud case for $20 million

Alere Inc, now a unit of Abbott Laboratories Inc, has agreed to pay $20 million to resolve claims it made false and misleading statements to investors in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott.

Abbott escapes lawsuit over recalled St. Jude defibrillators

Jan 25 - Abbott Laboratories has escaped a proposed class action lawsuit alleging its subsidiary St. Jude Medical concealed a potentially deadly battery defect in some of its cardiac defibrillators for years before finally recalling them in 2016.

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Abbott Labs says M&A not a high priority now

Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

Abbott resolves N.Y. claims over misleading infant-feeding surveys

Abbott Laboratories, the maker of Similac infant formula, has agreed to not falsely represent that surveys it mails new parents are for scientific research instead of marketing purposes and to accurately disclose their purpose.

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Select another date: